Evidence map›Paper›PMID 26350171›Full record

ReviewJournal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research2016

Managing Osteoporosis in Patients on Long-Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral Research.

Robert A Adler, Ghada El-Hajj Fuleihan, Douglas C Bauer, Pauline M Camacho, Bart L Clarke, Gregory A Clines, Juliet E Compston, Matthew T Drake, Beatrice J Edwards, Murray J Favus and 4 more

Erratum issuedOpen access · bronzeAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 236 papers, 15 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
236citing papers in PubMed, 15 pooled it
54.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

236 citing papers in PubMed, 15 syntheses or guidelines pooled it, 649 citations in OpenAlex.

  1. Guideline
  2. Pooled it
  3. Guideline
  4. Pooled it
  5. Guideline
  6. Guideline
  7. Guideline
  8. Pooled it
  9. Pooled it
  10. Guideline
  11. Pooled it
  12. Fracture risk following intermission of osteoporosis therapy.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2019
    Pooled it
  13. Pooled it
  14. A systematic review and meta-analysis of the effect of bisphosphonate drug holidays on bone mineral density and osteoporotic fracture risk.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2019
    Pooled it
  15. European guidance for the diagnosis and management of osteoporosis in postmenopausal women.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2019
    Guideline
  16. Trial
  17. Early changes in bone turnover and bone mineral density after discontinuation of long-term oral bisphosphonates: a post hoc analysis.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2021
    Trial
  18. Long-term cost-effectiveness of screening for fracture risk in a UK primary care setting: the SCOOP study.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2020
    Trial
  19. Comparison of BMD Changes and Bone Formation Marker Levels 3 Years After Bisphosphonate Discontinuation: FLEX and HORIZON-PFT Extension I Trials.Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2019
    Trial
  20. Addition of Zoledronate to Chemotherapy in Patients with Osteosarcoma Treated with Limb-Sparing Surgery: A Phase III Clinical Trial.Medical science monitor : international medical journal of experimental and clinical research · 2019
    Trial

176 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors at 13 institutions in 4 countries.

Robert A AdlerMcGuire Veterans Affairs Medical Center and Virginia Commonwealth University School of Medicine, Richmond, VA, USA.
Ghada El-Hajj FuleihanAmerican University of Beirut Medical Center, Beirut, Lebanon.
Douglas C BauerUniversity of California, San Francisco, San Francisco, CA, USA.
Pauline M CamachoLoyola University of Chicago, Maywood, IL, USA.
Bart L ClarkeMayo Clinic College of Medicine, Rochester, MN, USA.
Gregory A ClinesUniversity of Michigan, Ann Arbor, MI, USA.
Juliet E CompstonUniversity of Cambridge School of Clinical Medicine, Cambridge, UK.
Matthew T DrakeMayo Clinic College of Medicine, Rochester, MN, USA.
Beatrice J EdwardsMD Anderson Cancer Center, Houston, TX, USA.
Murray J FavusUniversity of Chicago, Chicago, IL, USA.
Susan L GreenspanUniversity of Pittsburgh, Pittsburgh, PA, USA.
Ross McKinneyDuke University School of Medicine, Durham, NC, USA.
Robert J PignoloUniversity of Pennsylvania, Philadelphia, PA, USA.
Deborah E SellmeyerThe Johns Hopkins Bayview Medical Center, Baltimore, MD, USA.
WinnMed · USAmerican University of Beirut Medical Center · LBCambridge School · PTChicago State University · USDuke University · USHunter Holmes McGuire VA Medical Center · USJohns Hopkins Bayview Medical Center · USThe University of Texas MD Anderson Cancer Center · USUniversity of California, San Francisco · USUniversity of Chicago · USUniversity of Michigan–Ann Arbor · USUniversity of Pennsylvania · USUniversity of Pittsburgh · US

Funding

VARIABILITY, STABILITY & SMOOTHNESS OF WALKINGP30AG024827 · NIA · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Caterina Rosano · 2004 to 2026
$28.6M
NIA NIH HHS P30 AG024827
6 · The paper itself

Abstract

Bisphosphonates (BPs) are the most commonly used medications for osteoporosis. This ASBMR report provides guidance on BP therapy duration with a risk-benefit perspective. Two trials provided evidence for long-term BP use. In the Fracture Intervention Trial Long-term Extension (FLEX), postmenopausal women receiving alendronate for 10 years had fewer clinical vertebral fractures than those switched to placebo after 5 years. In the HORIZON extension, women who received 6 annual infusions of zoledronic acid had fewer morphometric vertebral fractures compared with those switched to placebo after 3 years. Low hip T-score, between -2 and -2.5 in FLEX and below -2.5 in HORIZON extension, predicted a beneficial response to continued therapy. Hence, the Task Force suggests that after 5 years of oral BP or 3 years of intravenous BP, reassessment of risk should be considered. In women at high risk, for example, older women, those with a low hip T-score or high fracture risk score, those with previous major osteoporotic fracture, or who fracture on therapy, continuation of treatment for up to 10 years (oral) or 6 years (intravenous), with periodic evaluation, should be considered. The risk of atypical femoral fracture, but not osteonecrosis of the jaw, clearly increases with BP therapy duration, but such rare events are outweighed by vertebral fracture risk reduction in high-risk patients. For women not at high fracture risk after 3 to 5 years of BP treatment, a drug holiday of 2 to 3 years can be considered. The suggested approach for long-term BP use is based on limited evidence, only for vertebral fracture reduction, in mostly white postmenopausal women, and does not replace the need for clinical judgment. It may be applicable to men and patients with glucocorticoid-induced osteoporosis, with some adaptations. It is unlikely that future trials will provide data for formulating definitive recommendations. © 2015 American Society for Bone and Mineral Research.

Indexed as

Advisory CommitteesAge FactorsDiphosphonatesFemaleFemoral FracturesHumansImidazolesMaleOsteoporosisRisk FactorsSex FactorsSpinal FracturesZoledronic AcidDiphosphonatesImidazolesZoledronic AcidBISPHOSPHONATESDRUG HOLIDAYLONG TERM-BISPHOSPHONATE USEOTHER OSTEOPOROSIS THERAPIESRISK BENEFIT

Identifiers

PMID26350171
PMCPMC4906542
OpenAlexW1777836280

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.